Skip to content

Corcept 制药

US · CORT #1285 按市值排名 上市于 1970
110.16 -3.21 -2.83%
实时 - 追踪5344个代码 - 心跳于5秒前 · 2026-10-16 20:02

✦ 量化股权信号 计算方式说明

涨跌不一/平稳
  • 最近一期（2026/Q3）披露持股的机构数量增加了1家。
  • 机构持股总比例基本持平。

机构持股

机构持股比例
76.79% +0.06pp
机构数量
482 +1
数据截至
2026/Q3 较上一报告期

持股变动 vs 资金流向

方向分歧

机构在上一报告期增持了股份，同时该股在最近20个交易日的主力资金呈净流出——两者方向出现分歧。

机构持股变动数据按季度发布且存在滞后；资金流向数据为每日更新。请将其作为方向性的交叉验证参考，而非精确的择时信号。

持股人类型

Mutual Fund61.00%
Individual/Insider10.69%
Hedge Fund10.07%
Public Company1.67%
Government Pension Fund1.35%
VC/PE Fund1.08%
Private Company0.70%
Sovereign Wealth Fund0.45%
Insurance Company0.28%
Other12.71%

主要股东 截至 2026-06-30

BlackRock 11.50% · 12.43M 股
Ingalls & Snyder, LLC 7.34% · 7.93M 股
George Baker 5.13% · 5.55M 股
Renaissance Technologies Corp. 4.87% · 5.26M 股
Vanguard Portfolio Management, LLC 4.67% · 5.04M 股
Vanguard Capital Management, LLC 4.43% · 4.79M 股
Parallel Advisors, LLC 3.67% · 3.96M 股
FMR 3.09% · 3.34M 股
State Street Global Advisors 3.03% · 3.28M 股
Joseph Belanoff 2.65% · 2.87M 股

条形长度是相对于此处列出的最大股东而言，并非相对于公司100%股权。

内部人持股

共追踪50份申报 · 9次买入 · 39次卖出

姓名职务持股比例
George Baker Independent Director 5.13%
Joseph Belanoff Chief Executive Officer 2.65%
James Wilson Independent Chairperson 1.35%
David Mahoney Independent Director 1.07%
Hazel Hunt Chief Scientific Officer 0.24%
Sean Maduck President of Corcept Endocrinology 0.11%
Gary Robb Chief Business Officer & Secretary 0.09%
Atabak Mokari Chief Financial Officer 0.02%
Justin Gunn President of Endocrinology 0.01%
Joseph Lyon Chief Accounting Officer 0.01%
William Guyer Chief Development Officer 0.00%

内部人交易 最近的 Form 4 申报记录

日期姓名职务类型股数价格
2026-10-01 Joseph Lyon Chief Accounting Officer Derivative Exercise and Sale -10,000 $13.56–116.54
2026-10-01 Roberto Vieira President of Oncology Derivative Exercise and Sale -8,333 $21.63–116.59
2026-09-30 Joseph Lyon Chief Accounting Officer Intent to Sell (Form 144) -10,000 $115.23
2026-09-23 Gary Robb Chief Business Officer & Secretary Other Acquisition +10,000 --
2026-09-23 Gary Robb Chief Business Officer & Secretary Other Disposition -17,100 --
2026-09-16 Gary Robb Chief Business Officer & Secretary Derivative Exercise and Retained +17,493 $8.27
2026-09-15 Roberto Vieira President of Oncology Automatic Disposition -296 $100.82
2026-09-14 James Wilson Independent Chairperson Automatic Disposition -10,000 $110.27–111.70
2026-09-13 Joseph Lyon Chief Accounting Officer Derivative Exercise and Sale -10,000 $11.35–114.12
2026-09-01 Atabak Mokari Chief Financial Officer Sale to Issuer -102 $113.38
2026-09-01 Gary Robb Chief Business Officer & Secretary Sale to Issuer -91 $113.38
2026-09-01 Sean Maduck President of Corcept Endocrinology Sale to Issuer -117 $113.38
2026-09-01 Joseph Lyon Chief Accounting Officer Sale to Issuer -72 $113.38
2026-09-01 Roberto Vieira President of Oncology Sale to Issuer -102 $113.38
2026-09-01 Roberto Vieira President of Oncology Derivative Exercise and Sale -58,333 $21.63–115.44
2026-08-31 Atabak Mokari Chief Financial Officer Other Acquisition +276 $113.38
2026-08-31 Gary Robb Chief Business Officer & Secretary Other Acquisition +328 $113.38
2026-08-31 Sean Maduck President of Corcept Endocrinology Other Acquisition +300 $113.38
2026-08-31 Sean Maduck President of Corcept Endocrinology Derivative Exercise and Sale -25,000 $8.27–115.61
2026-08-31 Joseph Lyon Chief Accounting Officer Other Acquisition +260 $113.38

Form 4 申报记录，每家公司显示最新的一批。"Other Derivative Acquisition"（其他衍生品获取）类目多为限制性股票/期权归属，并非公开市场买入——具体类型见"类型"列。

报价时间 2026-10-16 20:02:28 · 仅供参考，不构成投资建议，也未考虑您的具体情况。

Corcept 制药 讨论区 0 条评论

发表评论